Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Products Administration (NMPA) for the treatment of ...

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first ...

GlycoEra’s lead candidate targets IgG4 autoantibodies, potentially addressing autoimmune diseases such as muscle-specific ...

Teva’s investigational monoclonal antibody, TEV-53408, has been designed for use in adults with celiac disease, for which a ...

It’s GlycoEra’s time to shine. The biotech has closed a series B fundraise clocking in at $130 million, with the funds set to ...

Proceeds from financing to support development of first-in-class IgG4-targeted protein degrader program through clinical proof-of-concept and the continued advancement of the company’s differentiated ...

As such, UCB’s recently-debuted, U.S.-based DTC rare-disease campaign Imagine Your Zillions supports its gMG treatment Zilbrysq. The effort is based on flipping the preconceived notions associated ...

LONDON, GREATER LONDON, UNITED KINGDOM, May 29, 2025 /EINPresswire.com/ -- What Does The C5 Complement Inhibitors Market Landscape Look Like? The market for C5 complement inhibitors, critical ...

The B-cell inhibitors market is experiencing robust growth, driven by the rising prevalence of the addressable patient population, which incl ...

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia ... market for the rare autoimmune and neuromuscular disease.

Angelini is paying $50 million upfront for ex-North American rights to radiprodil, with another $520 million in the offing in ...